Shasqi Raises $50 Million To Expand Click Chemistry Platform Beyond Injectable Tumors And Accelerate Lead Clinical Program
Shasqi Raises $50 Million To Expand Click Chemistry Platform Beyond Injectable Tumors And Accelerate Lead Clinical Program
11/11/21, 11:30 AM
Location
san franciscoMoney raised
$50 million
Shasqi, a clinical-stage biotechnology company developing precision activated oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPACTM) Platform, announced today a Series B funding round of $50 million driven by a syndicate of private investors, including Juan Jaen, Ph.D., President of Arcus Biosciences and Bill Rieflin, Executive Chairman of the Board at NGM Biopharmaceuticals. The funds will be used to advance the Phase 1/2 clinical study of SQ3370 for the treatment of injectable, advanced solid tumors, and will enable Shasqi to expand its click chemistry platform to create therapeutics that do not require intratumoral injections.
Company Info
Location
san francisco, california, united states
Additional Info
Shasqi is a privately held, clinical-stage biotechnology company whose mission is to enable patients to beat cancer with tumor-localized therapies. Shasqi leverages its proprietary CAPAC Platform to develop precision oncology therapeutics designed to deliver unprecedented doses precisely focused at the tumor with an uncharacteristically mild safety profile - breaking through the historic ceiling of dose-limiting toxicities. Shasqi's CAPAC Platform is highly modular and can be applied to a broad range of cancer drugs that are otherwise limited by toxicity, enabling the exploration of therapeutic biology in ways that were not previously possible.